Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Shares Issued (2020 - 2025)

Vivos Therapeutics has reported Shares Issued over the past 5 years, most recently at $4.7 million for Q4 2025.

  • Quarterly Shares Issued rose 34.57% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2025, down 3.55% year-over-year, with the annual reading at $5.6 million for FY2025, 25.65% down from the prior year.
  • Shares Issued was $4.7 million for Q4 2025 at Vivos Therapeutics, up from $2.4 million in the prior quarter.
  • Over five years, Shares Issued peaked at $8.0 million in Q1 2023 and troughed at -$4.0 million in Q4 2023.
  • The 4-year median for Shares Issued is $3.5 million (2024), against an average of $2.5 million.
  • The largest YoY upside for Shares Issued was 187.5% in 2024 against a maximum downside of 50.74% in 2024.
  • A 4-year view of Shares Issued shows it stood at $330000.0 in 2021, then plummeted by 1312.12% to -$4.0 million in 2023, then soared by 187.5% to $3.5 million in 2024, then surged by 34.57% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Shares Issued are $4.7 million (Q4 2025), $2.4 million (Q3 2025), and $3.5 million (Q4 2024).